<DOC>
	<DOCNO>NCT00105001</DOCNO>
	<brief_summary>This randomized phase II trial study well give tacrolimus mycophenolate mofetil ( MMF ) without sirolimus work prevent acute graft-versus-host disease ( GVHD ) patient undergo donor stem cell transplant hematologic cancer . Giving low dos chemotherapy , fludarabine phosphate , total-body-irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving MMF tacrolimus without sirolimus transplant may stop happening .</brief_summary>
	<brief_title>Tacrolimus Mycophenolate Mofetil With Without Sirolimus Preventing Acute Graft-Versus-Host Disease Patients Who Are Undergoing Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine 3 GVHD prophylaxis regimens result reduction acute grade II-IV GVHD = &lt; 40 % . SECONDARY OBJECTIVES : I . Reduce incidence non-relapse mortality infection GVHD day 200 = &lt; 15 % . II . Reduce utilization high-dose corticosteroid compare protocol 1463 , 1641 , 1668 . III . Compare survival progression-free survival achieve protocols 1463 , 1641 , 1668 . OUTLINE : CONDITIONING : All patient receive fludarabine phosphate intravenously ( IV ) 30 minute day -4 -2 undergo total-body irradiation day 0 . TRANSPLANTATION : All patient undergo allogeneic peripheral blood stem cell transplantation day 0 . IMMUNOSUPPRESSION : Patients randomize 1 3 treatment arm . ARM I : Patients receive tacrolimus IV orally ( PO ) every 12 hour day -3 180 taper begin day 100 absence GVHD . Patients also receive MMF PO every 8 hour day 0-29 every 12 hour day 30-96 taper begin day 40 absence GVHD . ARM II : Patients receive tacrolimus IV PO every 12 hour day -3 150 taper begin day 100 absence GVHD . Patients also receive MMF PO every 8 hour day 0-29 every 12 hour day 30-180 taper begin day 150 absence GVHD . ARM III : Patients receive tacrolimus MMF arm II . Patients also receive sirolimus PO daily day -3 80 . After completion study treatment , patient follow 6 month every year thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Ages &gt; 50 year hematologic malignancy treatable unrelated hematopoietic cell transplant ( HCT ) Ages = &lt; 50 year age hematologic diseases treatable allogeneic HCT preexist medical condition prior therapy consider high risk regimen relate toxicity associate conventional transplant ( &gt; 40 % risk transplant relate mortality [ TRM ] ) ( This criterion include patient HCTcomorbidity index ( CI ) score &gt; = 1 ; transplant approve inclusion criterion participate institution ' patient review committee Patient Care Conference ( PCC ) Fred Hutchinson Cancer Research Center ( FHCRC ) principal investigator collaborate center ) Patients = &lt; 50 year age receive previous highdose transplantation require patient review committee approval ( All child &lt; 12 year must discuss FHCRC principal investigator ( PI ) [ Brenda Sandmaier , MD 206 6674961 ] prior registration ) Ages = &lt; 50 year age chronic lymphocytic leukemia ( CLL ) ; patient require patient review committee approval Ages = &lt; 50 year age hematologic diseases treatable allogeneic HCT refuse conventional HCT ( Transplants must approve inclusion criterion participate institution ' patient review committee PCC FHCRC principal investigator collaborate center ) The following disease permit although diagnosis consider approve PCC participate institution ' patient review committee principal investigator : Aggressive nonHodgkin lymphoma ( NHL ) histologies Diffuse large B cell NHL eligible autologous hematopoietic stem cell transplant ( HSCT ) , eligible conventional myeloablative HSCT , fail autologous HSCT Mantle Cell NHL may treat first complete response ( CR ) ( Diagnostic lumbar puncture [ LP ] require pretransplant ) Low grade NHL &lt; 6 month duration CR course conventional therapy CLL must either Failed meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain fludarabine phosphate ( FLU ) ( another nucleoside analog , e.g . Cladribine [ 2CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain FLU ( another nucleoside analog ) ; Failed FLUCYRituximab ( FCR ) combination chemotherapy time point ; Have `` 17p deletion '' cytogenetic abnormality ; patient receive induction chemotherapy could transplant 1st CR Hodgkin Lymphoma must receive failed frontline therapy Multiple Myeloma must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HCT permit Acute Myeloid Leukemia ( AML ) must &lt; 5 % marrow blast time transplant Acute Lymphocytic Leukemia ( ALL ) must &lt; 5 % marrow blast time transplant Chronic Myeloid Leukemia ( CML ) patient accept beyond chronic phase ( CP ) 1 receive previous myelosuppressive chemotherapy HCT &lt; 5 % marrow blast time transplant Myelodysplasia ( MDS ) /Myeloproliferative Syndrome ( MPS ) patient must receive previous myelosuppressive chemotherapy HCT &lt; 5 % marrow blast time transplant Waldenstrom 's Macroglobulinemia must fail 2 course therapy DONOR : FHCRC match allow Grades 1.0 2.1 : unrelated donor prospectively : Matched human leukocyte antigen ( HLA ) A , B , C , DRB1 DQB1 high resolution type Only single allele disparity allow HLAA , B , C define high resolution type DONOR : Donors exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA Class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result ; positive antidonor cytotoxic crossmatch absolute donor exclusion DONOR : Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow DONOR : Only filgrastim ( GCSF ) mobilize peripheral blood mononuclear cell ( PBMC ) permit HSC source protocol Patients rapidly progressive intermediate high grade NHL Patients diagnosis chronic myelomonocytic leukemia ( CMML ) Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient AML , MDS , ALL CML Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant breastfeeding Patients active nonhematological malignancy ( except nonmelanoma skin cancer ) nonhematological malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within 5 year Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Cardiac ejection fraction &lt; 35 % ; ejection fraction require age &gt; 50 year history anthracycline exposure history cardiac disease Diffusion capacity carbon monoxide ( DLCO ) &lt; 40 % , total lung capacity ( TLC ) &lt; 40 % , forced expiratory volume one second ( FEV1 ) &lt; 40 % and/or receive supplementary continuous oxygen The FHCRC PI study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bridge fibrosis , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Karnofsky score &lt; 60 Lansky score &lt; 50 Patient poorly control hypertension multiple antihypertensives Human immunodeficiency virus ( HIV ) positive patient Active bacterial fungal infection unresponsive medical therapy All patient receive antifungal therapy voriconazole , posaconazole , fluconazole randomize ARM 3 must rapamycin reduce accord Standard Practice Antifungal Therapy Guidelines The addition cytotoxic agent cytoreduction exception tyrosine kinase inhibitor ( imatinib ) , cytokine therapy , hydroxyurea , low dose cytarabine , chlorambucil , Rituxan allow within three week initiation condition DONOR : Donor ( center ) exclusively donate marrow DONOR : Donors HIVpositive and/or , medical condition would result increase risk GCSF mobilization harvest GPBMC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>